TAMPA, FL--(Marketwire - March 25, 2008) - Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") is pleased to announce the signing of a research collaboration agreement with BioChemics Inc. (BCI) to utilize BCI's leading patented drug delivery technology (VALE®) for the transdermal (topical) delivery of Nanobac compounds for the treatment of prostatitis. Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BCI.
